World Aquaculture Singapore 2026

June 2-5, 2026

Singapore

NEXT-GENERATION FISH VACCINES: ECONOMIC IMPACT OF CHIMERIC MULTI-EPITOPE DESIGN AND ORAL NANO-DELIVERY SYSTEMS IN Oreochromis spp. AQUACULTURE

Sasimanas Unajak1,* , Ansaya Pumchan1 , Ikuo Hirono2 , Hidehiro Kondo2

1Department of Biochemistry, Faculty of Science, Kasetsart University
50 Ngam Wong Wan, Chatuchak, Bangkok 10900, Thailand

2Graduate School of Marine Science and Technology, Tokyo University of Marine Science and Technology, Konan 4_5_7, Minato_KU, Tokyo 108_8477, Japan.
sasimanas.u@ku.th



The global aquaculture industry faces a critical profitability bottleneck driven by synergistic pathogenic co-infections and escalating antibiotic resistance. For commercial operations relying on reactive antibiotic treatments, this immune collapse results in unpredictable catastrophic losses ranging from 65% to 90%. To secure sustainable production and profitability, the private sector must transition to proactive, scalable vaccination strategies. This presentation details the commercial development and field efficacy of Generation 3 Structural Vaccinology and advanced oral delivery platforms designed for large-scale implementation in aquaculture.

Traditional whole-cell (Generation 1) and recombinant (Generation 2) vaccines, while effective, present significant commercial limitations regarding strain coverage and labor-intensive injection delivery. For example, combining TiLV segments 9 and 10 in DNA and recombinant protein vaccines conferred superior protection compared to single-segment approaches, offering comprehensive defense against multiple distinct threats in a single formulation. Here, we introduce Chimeric Multi-Epitope Vaccines (CMEV) (Generation 3), a precision-engineered platform that combines multiple distinct antigenic epitopes into a single construct. In our trials, the CMEV formulation (Vaxstrep 4.2) targeting streptococcosis demonstrated enhanced antigenicity (>0.75) and high stability (>0.7), yielding a Relative Percentage Survival (RPS) of 57–76% against Streptococcus agalactiae challenge (1 × 10⁷ CFU/mL), which is not significantly different from the traditional whole-cell bivalent vaccine.

Crucially for commercial scalability, we addressed the labor and stress limitations of injectable vaccines with a novel nanotechnology-based oral delivery system using modified Halloysite Nanotubes (HNTs). By encapsulating antigens in HNT-APTES-Chitosan (HAC) matrices, we achieved stress-free, feed-based administration, thereby protecting the antigens from gastric degradation. This oral nano-delivery system demonstrated a remarkable 75.00% RPS, achieving an efficacy statistically comparable to that of traditional intraperitoneal injection (81.25% RPS) while eliminating injection-associated labor costs and handling stress. For entrepreneurs and farmers, integrating these advanced vaccination platforms with Specific Pathogen-Free (SPF) genetics yields exceptional economic returns. Field evidence confirms that  this integrated approach harmonizes growth, provides 10-month protection, and maintains mortality below 35%. Most significantly, eliminating the critical 1-month TiLV die-off through SPF integration and vaccination generates a documented profit gain. This research provides a validated commercial roadmap for implementing scalable, highly profitable, and antibiotic-free aquaculture systems globally.